Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease

Abstract

Background

Cidofovir is currently being used off-licence to treat different viral infections, such as benign low-risk human papillomavirus (HPV)-related recurrent respiratory papillomatosis (RRP). There are concerns over the safety of this practice as rat studies demonstrated a high malignant transformation rate. As yet, there are no clinical reports of cidofovir-induced malignant changes in humans.

Methods

Telomerase immortalised human keratinocytes (hTert) stably expressing E6 proteins from either low-risk HPV6b or high-risk HPV16 and vector control cells were treated with either low-dose (5 μg/ml) or higher dose (30 μg/ml) cidofovir for 2 days and the effects evaluated by clonogenic survival assays. Based on these results, gene expression microarray analysis was performed on cidofovirtreated low-risk E6 and vector cells before, during and after drug treatment, and the results verified by real-time PCR.

Results

Both low-risk and high-risk E6-expressing cells show significantly improved long-term survival compared with vector control cells when exposed to 5 μg/ml cidofovir for 2 days, (hTert T6E6 P=0.0007, hTert T16E6 P=0.00023 and hTert vector control P=0.62). Microarray and real-time PCR analyses of low-dose cidofovir-treated low-risk E6-expressing cells revealed changes in gene expression that are known to be associated with malignant progression, which were not observed in drug-treated vector control cells.

Conclusions

This is the first report that cidofovir can both increase cell survival and induce alterations in gene expression that are known to be associated with malignant transformation in cells transduced only with the E6 gene from low-risk HPV. It is our belief that these data provide cause for concern over the off-license use of this drug to treat RRP.

References

de Clercq

Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.

Verh K Acad Geneeskd Belg 1996; 58: 19–47.

Donne

A.J.

, Hampson

, He

X.T.

Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis.

Head Neck 2007; 29: 741–750.

Araya

C.E.

, Lew

J.F.

, Fennell

R.S.

, Neiberger

R.E.

, Dharnidharka

V.R.

Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy.

Pediatr Transplant 2008; 12: 790–795.

Yoshizaki

, Wakisaka

, Kondo

Treatment of locally recurrent Epstein–Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir.

J Med Virol 2008; 80: 879–882.

Anderson

E.J.

, Guzman-Cottrill

J.A.

, Kletzel

High-risk adenovirus-infected pediatric allogeneic haematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy.

Pediatr Transplant 2008; 12: 219–227.

Cusack

, Fitzgerald

, Clayton

T.M.

Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11-year-old girl.

Pediatr Dermatol 2008; 25: 387–389.

Derkay

C.S.

Task force on recurrent respiratory papillomas. A preliminary report.

Arch Otolaryngol Head Neck Surg 1995; 121: 1386–1391.

Inglis

A.F.

Jr. , Cidofovir and the black box warning. Ann Otol Rhinol Laryngol 2005; 114: 834–835.

Abdulkarim

, Sabri

, Deutsch

Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.

Oncogene 2002; 21: 2334–2346.

10.

Sirianni

, Wang

, Ferris

R.L.

Antiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity.

Oral Oncol 2005; 41: 423–428.

11.

Kramata

, Votruba

, Otova

Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon.

Mol Pharmacol 1996; 49: 1005–1011.

12.

De Clercq

, Holy

Acyclic nucleoside phosphonates: a key class of antiviral drugs.

Nat Rev Drug Discov 2005; 4: 928–940.

13.

Shin

K.H.

, Park

K.H.

, Hong

H.J.

Prevalence of microsatellite instability, inactivation of mismatch repair genes, p53 mutation, and human papillomavirus infection in Korean oral cancer patients.

Int J Oncol 2002; 21: 297–302.

14.

Shin

K.H.

, Ahn

J.H.

, Kang

M.K.

HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and -independent pathways.

Int J Oncol 2006; 28: 209–215.

15.

Band

, Dalal

, Delmolino

Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells.

EMBO J 1993; 12: 1847–1852.

16.

Duensing

, Munger

Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins.

Int J Cancer 2004; 109: 157–162.

17.

Hampson

, Kitchener

H.C.

, Hampson

I.N.

Specific HIV protease inhibitors inhibit the ability of HPV 16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.

Antivir Ther 2006; 11: 813–825.

18.

Vandesompele

, De

P.K.

, Pattyn

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Genome Biol 2002; 3: RESEARCH0034.

19.

Brown

J.M.

, Attardi

L.D.

The role of apoptosis in cancer development and treatment response.

Nat Rev Cancer 2005; 5: 231–237.

20.

Lalezari

J.P.

, Drew

W.L.

, Glutzer

(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue.

J Infect Dis 1995; 171: 788–796.

21.

Albright

J.T.

, Pransky

S.M.

Update on the use of cidofovir for managing recurrent respiratory papillomatosis.

ENT News 2003; 12: 71–73.

22.

Mammas

I.N.

, Sourvinos

, Michael

Human papilloma virus in hyperplastic tonsillar and adenoid tissues in children.

Pediatr Infect Dis J 2006; 25: 1158–1162.

23.

Sisk

, Schweinfurth

J.M.

, Wang

X.T.

Presence of human papillomavirus DNA in tonsillectomy specimens.

Laryngoscope 2006; 116: 1372–1374.

24.

Smith

E.M.

, Pignatari

S.S.

, Gray

S.D.

Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction.

Arch Otolaryngol Head Neck Surg 1993; 119: 554–557.

25.

Mori

, Krensky

A.M.

, Ohshima

Elevated expression of CCL5/RANTES in adult T-cell leukaemia cells: possible transactivation of the CCL5 gene by human T-cell leukemia virus type I tax.

Int J Cancer 2004; 111: 548–557.

26.

Uchihara

J.N.

, Krensky

A.M.

, Matsuda

Transactivation of the CCL5/RANTES gene by Epstein–Barr virus latent membrane protein 1.

Int J Cancer 2005; 114: 747–755.

27.

Niwa

, Akamatsu

, Niwa

Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer.

Clin Cancer Res 2001; 7: 285–289.

28.

Schall

T.J.

, Bacon

, Toy

K.J.

Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES.

Nature 1990; 347: 669–671.

29.

Pritchard

, Han

, Horst

Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway.

J Immunol 2003; 170: 6348–6354.

30.

Burrow

, Andrulis

I.L.

, Pollak

Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma.

J Surg Oncol 1998; 69: 21–27.

31.

Ulfarsson

, Karstrom

, Yin

Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach.

Clin Cancer Res 2005; 11: 4674–4680.

32.

Girnita

, Girnita

, Brodin

Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.

Cancer Res 2000; 60: 5278–5283.

33.

Baserga

The insulin-like growth factor I receptor: a key to tumor growth?

Cancer Res 1995; 55: 249–252.

34.

Larsson

, Girnita

Role of insulin-like growth factor 1 receptor signalling in cancer.

Br J Cancer 2005; 92: 2097–2101.

35.

Shellenberger

T.D.

, Mazumdar

, Henderson

Headpin: a serpin with endogenous and exogenous suppression of angiogenesis.

Cancer Res 2005; 65: 11501–11509.

36.

Garcia

M.J.

, Pole

J.C.

, Chin

S.F.

A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.

Oncogene 2005; 24: 5235–5245.

37.

Ivanov

, Lo

K.C.

, Hawthorn

Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells.

Oncogene 2007; 26: 2873–2884.

38.

Chen

, Pacyna-Gengelbach

, Deutschmann

Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer.

Int J Cancer 2007; 121: 1021–1027.

39.

Lemaire

, Millon

, Muller

Loss of HOP tumour suppressor expression in head and neck squamous cell carcinoma.

Br J Cancer 2004; 91: 258–261.

40.

Zhao

L.Y.

, Liao

Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis.

J Virol 2003; 77: 13171–13181.

41.

Jang

S.I.

, Kalinin

, Takahashi

Characterization of human epiplakin: RNAi-mediated epiplakin depletion leads to the disruption of keratin and vimentin IF networks.

J Cell Sci 2005; 118: 781–793.

42.

Goto

, Sumiyoshi

, Sakai

Elimination of epiplakin by gene targeting results in acceleration of keratinocyte migration in mice.

Mol Cell Biol 2006; 26: 548–558.

43.

Lott

D.G.

, Krakovitz

P.R.

Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis.

Laryngoscope 2009; 119: 567–570.

44.

Eisenbeis

J.F.

, Sappington

J.M.

The effect of cidofovir injection concurrent with surgical resection for adult onset recurrent respiratory papillomatosis.

Laryngoscope 2009; 119 Suppl 1: S96.

45.

Carvalho

C.M.

, Huot

, Charlois

A.L.

Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients.

Acta Otolaryngol 2009; 129: 462–470.

46.

Broekema

F.I.

, Dikkers

F.G.

Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis.

Eur Arch Otorhinolaryngol 2008; 265: 871–879.

47.

Poetker

D.M.

, Patel

N.J.

, Kerschner

J.E.

Cidofovir modulated gene expression in recurrent respiratory papillomatosis.

Int J Pediatr Otorhinolaryngol 2008; 72: 1385–1392.

48.

McMurray

J.S.

, Connor

, Ford

C.N.

Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study.

Ann Otol Rhinol Laryngol 2008; 117: 477–483.

49.

Lewis

T.E.

, Milam

T.D.

, Klingler

D.W.

Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer.

Urol Oncol 2005; 23: 407–412.

50.

Wirtenberger

, Tchatchou

, Hemminki

Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer.

Carcinogenesis 2006; 27: 593–598.

51.

Capurso

, Lattimore

, Crnogorac-Jurcevic

Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets.

Endocr Relat Cancer 2006; 13: 541–558.

52.

Riker

A.I.

, Enkemann

S.A.

, Fodstad

The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.

BMC Med Genomics 2008; 1: 13.

53.

Cahill

D.P.

, Lengauer

, Yu

Mutations of mitotic checkpoint genes in human cancers.

Nature 1998; 392: 300–303.

54.

Yoon

, Molloy

M.J.

, Wu

M.P.

C6ORF32 is upregulated during muscle cell differentiation and induces the formation of cellular filopodia.

Dev Biol 2007; 301: 70–81.

55.

Luboshits

, Shina

, Kaplan

Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.

Cancer Res 1999; 59: 4681–4687.

56.

Vaday

G.G.

, Peehl

D.M.

, Kadam

P.A.

Expression of CCL5 (RANTES) and CCR5 in prostate cancer.

Prostate 2006; 66: 124–134.

57.

, Bjorck

, Hogerkorp

C.M.

Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival.

Int J Cancer 2006; 118: 2092–2097.

58.

Aldinucci

, Lorenzon

, Cattaruzza

Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.

Int J Cancer 2008; 122: 769–776.

59.

Kashibuchi

, Tomita

, Schalken

J.A.

The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy.

Int J Urol 2007; 14: 789–794.

60.

Fujita

, Furukawa

, Tsunoda

Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor complex, in colorectal carcinomas.

Cancer Res 2001; 61: 7722–7726.

61.

Xiang

, Fan

S.Q.

, Li

Expression of connexin43 and connexin45 in nasopharyngeal carcinoma.

Ai Zheng 2002; 21: 593–596. [Chinese].

62.

Hayashi

, Kuramitsu

, Okada

Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines.

Proteomics 2005; 5: 1024–1032.

63.

Suomela

, Cao

, Bowcock

Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers.

J Invest Dermatol 2004; 122: 717–721.

64.

Taguchi

, Kato

, Baba

Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.

Oncol Rep 2004; 11: 421–426.

65.

Dong

, Kong

, Ma

Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells.

Acta Biochim Biophys Sin (Shanghai) 2008; 40: 497–504.

66.

Liu

, Bloom

D.A.

, Cance

W.G.

FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.

Carcinogenesis 2008; 29: 1096–1107.

67.

Sroka

I.C.

, McDaniel

, Nagle

R.B.

Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression.

Prostate 2008; 68: 463–476.

68.

Oshikawa

, Yanagisawa

, Ohno

Expression of ST2 in helper T lymphocytes of malignant pleural effusions.

Am J Respir Crit Care Med 2002; 165: 1005–1009.

69.

Shimada

, Kuboshima

, Shiratori

Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma.

Int J Oncol 2007; 30: 97–103.

70.

Kim

T.J.

, Choi

J.J.

, Kim

W.Y.

Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer.

Cancer Sci 2008; 99: 31–38.

71.

Pinheiro

, Longatto-Filho

, Ferreira

Increasing Expression of Monocarboxylate Transporters 1 and 4 Along Progression to Invasive Cervical Carcinoma.

Int J Gynecol Pathol 2008; 27: 568–574.

72.

Pinheiro

, Longatto-Filho

, Scapulatempo

Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas.

Virchows Arch 2008; 452: 139–146.

73.

Raman

, Earnest

, Zhang

TAO kinases mediate activation of p38 in response to DNA damage.

EMBO J 2007; 26: 2005–2014.

74.

Park

, Dean

, Cooper

C.S.

Mechanism of met oncogene activation.

Cell 1986; 45: 895–904.

75.

Liu

, Gao

, Chen

HBP21: A Novel Member of TPR Motif Family, as a Potential Chaperone of Heat Shock Protein 70 in Proliferative Vitreoretinopathy (PVR) and Breast Cancer.

Mol Biotechnol 2008; 40: 231–240.

76.

Jackson

R.S.

, Cho

Y.J.

, Liang

TIS11D is a candidate pro-apoptotic p53 target gene.

Cell Cycle 2006; 5: 2889–2893.